Literature DB >> 20367772

Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.

Alan W Shindel1, Guiting Lin2, Hongxiu Ning2, Lia Banie2, Yun-Ching Huang2, Gang Liu2, Ching-Shwun Lin2, Tom F Lue2.   

Abstract

INTRODUCTION: Transforming growth factor-β1 (TGF-β1) has been implicated in the pathogenesis of Peyronie's disease (PD) and also plays a role in collagen and elastin metabolism. Pentoxifylline (PTX) antagonizes the effects of TGF-β1 and has been utilized in our clinic for the management of PD. AIM: We studied the effects of TGF-β1 and PTX on collagen metabolism and elastogenesis in tunica albuginea-derived fibroblasts (TADFs).
METHODS: TADFs from men with and without PD were cultured and treated with TGF-β1 and PTX as monotherapy at differing concentrations and time points. Combination treatment (TGF-β1 followed by PTX and vice versa) was also investigated. MAIN OUTCOME MEASURES: Cell proliferation assay, enzyme-linked immunosorbent assay, and immunohistochemistry were utilized to assess the impact of TGF-β1 and PTX on TADF with respect to elastin and collagen I metabolism.
RESULTS: PTX inhibited fibroblast proliferation at doses of 100 µM. TGF-β1 stimulated elastogenesis and collagen I fiber deposition in TADF in a dose- and time-dependent fashion. Pretreatment with PTX dramatically attenuated TGF-β1-mediated elastogenesis and collagen fiber deposition in TADF from men with and without PD. Interestingly, production of collagen I was higher in untreated Peyronie's tunica (PT) cells relative to normal tunica (NT) cells; furthermore, PTX attenuated collagen production to levels similar to untreated control TADF in PT cells but not in NT cells, suggesting important intrinsic differences between PT and NT cells.
CONCLUSION: Both elastin and collagen are upregulated by TGF-β1 in TADF. This likely contributes to the PD phenotype. Pretreatment with PTX attenuates both collagen fiber deposition and elastogenesis in TADF exposed to TGF-β1; these effects suggest a useful role for PTX in the management of PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367772      PMCID: PMC3543151          DOI: 10.1111/j.1743-6109.2010.01790.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  36 in total

1.  Identification of potential biomarkers of Peyronie's disease.

Authors:  Gui-Ting Lin; Zhong Wang; Ben-Chun Liu; Tom F Lue; Ching-Shwun Lin
Journal:  Asian J Androl       Date:  2005-09       Impact factor: 3.285

2.  Activation of elastin transcription by transforming growth factor-beta in human lung fibroblasts.

Authors:  Ping-Ping Kuang; Xiao-Hui Zhang; Celeste B Rich; Judith A Foster; Mangalalaxmy Subramanian; Ronald H Goldstein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-01-05       Impact factor: 5.464

3.  Treatment of Peyronie's disease with oral pentoxifylline.

Authors:  William O Brant; Robert C Dean; Tom F Lue
Journal:  Nat Clin Pract Urol       Date:  2006-02

4.  Structural alterations in the tunica albuginea of the penis: impact of Peyronie's disease, ageing and impotence.

Authors:  E Akkus; S Carrier; K Baba; G L Hsu; H Padma-Nathan; L Nunes; T F Lue
Journal:  Br J Urol       Date:  1997-01

5.  Role of increased transforming growth factor beta protein expression in the pathogenesis of Peyronie's disease.

Authors:  Howayda Hassoba; Ahmed El-Sakka; Tom Lue
Journal:  Egypt J Immunol       Date:  2005

6.  Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression.

Authors:  A I El-Sakka; H M Hassoba; R J Pillarisetty; R Dahiya; T F Lue
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

7.  Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor.

Authors:  Shuei-Liong Lin; Ruey-Hwa Chen; Yung-Ming Chen; Wen-Chih Chiang; Chun-Fu Lai; Kwan-Dun Wu; Tun-Jun Tsai
Journal:  J Am Soc Nephrol       Date:  2005-06-29       Impact factor: 10.121

8.  Pentoxifylline attenuates lung injury and modulates transcription factor activity in hemorrhagic shock.

Authors:  Jessica Deree; Joilson Martins; Tercio de Campos; James G Putnam; William H Loomis; Paul Wolf; Raul Coimbra
Journal:  J Surg Res       Date:  2007-11       Impact factor: 2.192

Review 9.  TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring.

Authors:  Kenneth R Cutroneo
Journal:  Wound Repair Regen       Date:  2007 Sep-Oct       Impact factor: 3.617

10.  Latent TGF-beta-binding protein 2 binds to DANCE/fibulin-5 and regulates elastic fiber assembly.

Authors:  Maretoshi Hirai; Masahito Horiguchi; Tetsuya Ohbayashi; Toru Kita; Kenneth R Chien; Tomoyuki Nakamura
Journal:  EMBO J       Date:  2007-06-21       Impact factor: 11.598

View more
  25 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

3.  TGF-beta 1 is a potential regulator of vaginal tropoelastin production.

Authors:  Peter Takacs; Yanping Zhang; Sujata Yavagal; Keith Candiotti; Nahida Chakhtoura; Carlos A Medina
Journal:  Int Urogynecol J       Date:  2011-11-09       Impact factor: 2.894

4.  Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction.

Authors:  Maarten Albersen; Thomas M Fandel; Haiyang Zhang; Lia Banie; Guiting Lin; Dirk De Ridder; Ching-Shwun Lin; Tom F Lue
Journal:  Eur Urol       Date:  2010-10-26       Impact factor: 20.096

Review 5.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 6.  Update on medical management of Peyronie's disease.

Authors:  Ronny B W Tan; Premsant Sangkum; Gregory C Mitchell; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

Review 7.  Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.

Authors:  Ayad Yousif; Caleb Natale; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2021-01-08       Impact factor: 3.092

8.  The effect of pentoxifylline on detrusor muscle contractility after partial urethral obstruction in a rat model.

Authors:  Mehdi Shirazi; Hossein Mirkhani; Ahmad Monabbati; Soheil Moghtadernejad; Alireza Aminsharifi
Journal:  Int Urol Nephrol       Date:  2015-07-19       Impact factor: 2.370

9.  Optimizing postoperative sexual function after radical prostatectomy.

Authors:  Manuela Tutolo; Alberto Briganti; Nazareno Suardi; Andrea Gallina; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Niccolò Passoni; Alessandro Nini; Nicola Fossati; Patrizio Rigatti; Francesco Montorsi
Journal:  Ther Adv Urol       Date:  2012-12

10.  Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis.

Authors:  Milica Ćulafić; Sandra Vezmar-Kovačević; Violeta Dopsaj; Branislav Oluić; Nemanja Bidžić; Branislava Miljković; Đorđe Ćulafić
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.